¼¼°èÀÇ ¼¼³î¸®Æ½ ¾à¹° ½ÃÀå : ÇâÈÄ ¿¹Ãø(-2032³â)
Senolytic Drugs Market Forecasts to 2032 - Global Analysis By Drug Type (Dasatinib, Quercetin, Navitoclax, Fisetin, FOXO4-DRI and Other Drug Types), Mechanism of Action, Route of Administration, Application, End User and By Geography
»óǰÄÚµå : 1797919
¸®¼­Ä¡»ç : Stratistics Market Research Consulting
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 200+ Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,150 £Ü 5,849,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,250 £Ü 7,399,000
PDF (2-5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 5ȸ±îÁö °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,350 £Ü 8,950,000
PDF & Excel (Site License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 5ȸ±îÁö °¡´ÉÇÕ´Ï´Ù. Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ¹× Excel ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,500 £Ü 10,571,000
PDF & Excel (Global Site License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 10ȸ±îÁö °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Stratistics MRC¿¡ µû¸£¸é ¼¼°èÀÇ ¼¼³î¸®Æ½ ¾à¹° ½ÃÀåÀº 2025³â 5,850¸¸ ´Þ·¯¸¦ Â÷ÁöÇϰí, 2032³â¿¡´Â 5¾ï 5,250¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¿¹Ãø ±â°£ µ¿¾È CAGRÀº 37.8%¸¦ ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù.

¼¼³î¸®Æ½ ¾à¹°Àº ¼¼Æ÷ºÐ¿­Àº Á¤ÁöÇϰí ÀÖÁö¸¸ ´ë»ç´Â Ȱ¹ßÇÏ¸ç ³ëÈ­¿Í ¸¸¼ºÁúȯÀÇ ¿øÀÎÀÌ µÇ´Â ¼¼Æ÷ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ±â´ÉºÎÀü¿¡ ºüÁø ¼¼Æ÷¸¦ Á¦°ÅÇÔÀ¸·Î½á, ¼¼³î¸®Æ½ ¾à¹°Àº ¿°ÁõÀ» ¾ïÁ¦Çϰí, Á¶Á÷±â´ÉÀ» ȸº¹½Ã۰í, ³ëÈ­¿¡ ÀÇÇÑ ¼èÅ𸦠Áö¿¬½ÃŰ´Â °ÍÀ» ¸ñÀûÀ¸·Î Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ È­ÇÕ¹°Àº °ñ°üÀý¿°, ¼¶À¯Áõ, ½ÉÇ÷°ü°è ¹®Á¦, ½Å°æÅðÇ༺ Áúȯ µîÀÇ Ä¡·á¿¡ À¯¸ÁÇÕ´Ï´Ù. õ¿¬ À¯·¡ ¶Ç´Â ½ÇÇè½Ç¿¡¼­ ÇÕ¼ºµÈ ¼¼³î¸®Æ½ ¾à¹°Àº ³ëÈ­ ¼¼Æ÷ ³»ÀÇ Æ¯Á¤ »ýÁ¸ °æ·Î¸¦ Ç¥ÀûÀ¸·Î ÇÕ´Ï´Ù. ¿¬±¸°¡ ÁøÇàµÊ¿¡ µû¶ó Àå¼ö °úÇÐ, Àç»ý ÀÇ·á, ¼¼Æ÷ ȸÃá¿¡ ÁßÁ¡À» µÐ ¿¹¹æ ÀÇ·á Àü·«¿¡¼­ Çõ½ÅÀûÀÎ µµ±¸·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù.

¿¬·É °ü·Ã ÁúȯÀÇ À¯º´·ü »ó½Â

³ëÈ­¿Í °ü·ÃµÈ Áúº´ÀÇ À¯º´·ü Áõ°¡´Â Çö´ë Ä¡·á¿¡¼­ Áß¿äÇÑ Çõ½ÅÀ¸·Î ÀÚ¸®¸Å±èÇÏ°í ¼¼³î¸®Æ½ ¾à¹° ¼ö¿ä¸¦ Å©°Ô °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. ¾ËÃ÷ÇÏÀ̸Ӻ´, ½ÉÇ÷°ü Àå¾Ö, °ñ°üÀý¿° µîÀÇ Ä¡·á°¡ ³ëÈ­¸¦ Ç¥ÀûÀ¸·Î ÇÏ´Â Ä¡·á¹ýÀÇ ¿¬±¸¿Í ä¿ëÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ¼¼°è Àα¸°¡ °í·ÉÈ­µÊ¿¡ µû¶ó ÀÇ·á ½Ã½ºÅÛÀº È¿°úÀûÀÎ Áúº´ ¼öÁ¤ ¼Ö·ç¼ÇÀ» Á¡Á¡ ´õ ¸¹ÀÌ ¿ä±¸Çϰí ÀÖ½À´Ï´Ù. ¼¼Æ÷ÀÇ ³ëÈ­¸¦ ±Ùº»ÀûÀ¸·Î ÇØ°áÇÏ´Â ¼¼³î¸®Æ½ ¾à¹°Àº ȹ±âÀûÀÎ ¾àÀ¸·Î ÁöÁö¸¦ ¸ðÀ¸°í, ÀÓ»óÀûÀΠŽ±¸¸¦ È®´ëÇϰí, ÀǾàǰ°ú À£´Ï½º ¿µ¿ª¿¡¼­ ½ÃÀåÀÇ °­·ÂÇÑ ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.

Á¦ÇÑµÈ ÀÓ»ó Áõ°Å¿Í ±ÔÁ¦ ºÒÈ®½Ç¼º

¼¼³î¸®Æ½ ¾à¹° ½ÃÀåÀº Á¦ÇÑµÈ ÀÓ»ó Áõ°Å¿Í ±ÔÁ¦ ºÒÈ®½Ç¼ºÀ¸·Î ÀÎÇØ Å« ÈÄÅð¿¡ Á÷¸éÇϰí ÀÖ½À´Ï´Ù. °ß°íÇÏ°í ´ë±Ô¸ð ÀÓ»ó½ÃÇèÀÌ ÀÌ·ç¾îÁöÁö ¾Ê¾Ò±â ¶§¹®¿¡ ¾ÈÀü¼º°ú È¿´É¿¡ ÀǽÉÀÌ »ý°Ü ÀÓ»óÀÇ¿Í È¯ÀÚÀÇ ½Å·Ú°¡ ÀúÇϵǰí ÀÖ½À´Ï´Ù. µ¿½Ã¿¡, ºÒ¸íÈ®ÇÏ°í °³¹ß µµ»óÀÇ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©ÀÌ ½ÂÀο¡ ´ëÇÑ À庮ÀÌ µÇ¾î »ó¾÷È­¸¦ ´ÊÃß°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀÎÀº ÅõÀÚÀÚÀÇ ½Å·Ú¸¦ Á¦ÇÑÇϰí, ¿¬±¸ÀÇ ÁøÀüÀ» ´ÊÃß°í, Ä¡·áÀÇ °¡´É¼º¿¡µµ ºÒ±¸Çϰí, ³ëÈ­¼¼Æ÷Á¦°Å ¿ä¹ýÀÇ ±¤¹üÀ§ÇÑ Ã¤¿ëÀ» ¹æÇØÇϰí ÀÖ½À´Ï´Ù.

Àå¼ö¿Í °Ç°­ ³ëÈ­¿¡ ´ëÇÑ °ü½É Áõ°¡

Àå¼ö¿Í °Ç°­ÇÑ ³ëÈ­¿¡ ´ëÇÑ °ü½É Áõ°¡´Â ¼¼³î¸®Æ½ ¾à¹°¿¡ ´ëÇÑ Àü·Ê¾ø´Â ¼ö¿ä¸¦ ÃËÁøÇÕ´Ï´Ù. ¼ÒºñÀÚ¿Í ÀÇ·á ½Ã½ºÅÛÀÌ ¼ö¸íº¸´Ù °Ç°­ ¼ö¸í ¿¬ÀåÀ» ¼±È£ÇÏ°Ô µÇ¾î ¼¼Æ÷ÀÇ È¸Ãá ±â¼ú¿¡ ´ëÇÑ ÅõÀÚ°¡ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. À¯ÇØÇÑ ³ëÈ­ ¼¼Æ÷¸¦ Á¦°ÅÇÏ´Â ¼¼³î¸®Æ½ ¾à¹°Àº ¿¹¹æ ÀÇÇÐ ¹× À£ºù µ¿Çâ°ú ¿Ïº®ÇÏ°Ô ÀÏÄ¡ÇÕ´Ï´Ù. Ȱ·ÂÀ» ³ôÀÌ°í ³ëÈ­·Î ÀÎÇÑ ¼èÅ𸦠¾ïÁ¦ÇÏ°í »îÀÇ ÁúÀ» Çâ»ó½ÃŰ´Â ¿ªÇÒÀº Á¦¾à, »ý¸í °øÇÐ ¹× ¿µ¾ç º¸Á¶ ½Äǰ ºÐ¾ß¿¡¼­ °ü½ÉÀ» ²ø°í ÀÖ½À´Ï´Ù. ÀÌ ¹®È­Àû, °úÇÐÀû º¯È­´Â ¼¼°èÀÇ ±â¼ú Çõ½Å, ÀÎÁöµµ Çâ»ó, ½ÃÀå È®´ë¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

³ôÀº °³¹ß ºñ¿ë

º¹ÀâÇÑ ¿¬±¸, ±¤¹üÀ§ÇÑ ÀÓ»ó½ÃÇè, ±ÔÁ¦ ¿ä°Ç¿¡´Â ¸¹Àº ÀÚ±Ý ÅõÀÚ°¡ ÇÊ¿äÇϱ⠶§¹®¿¡ ³ôÀº °³¹ß ºñ¿ëÀÌ ¼¼³î¸®Æ½ ¾à¹° ½ÃÀåÀÇ ÁÖ¿ä Àå¾Ö¹°ÀÌ µÇ¾ú½À´Ï´Ù. ¼Ò±Ô¸ð ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷¿¡¼­´Â ÃæºÐÇÑ ÀÚ±Ý È®º¸¿¡ ¾î·Á¿òÀÌ ¸¹°í, ±â¼ú Çõ½ÅÀ̳ª Á¦Ç° Ãâ½Ã°¡ ´Ê¾îÁö°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ °í°¡ÀÇ ÁöÃâÀº ÅõÀÚÀÚÀÇ À§ÇèÀ» Áõ°¡½Ã۰í, ½ÃÀå È®´ë¸¦ ´ÊÃß°í, ÀáÀçÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇÑ Á¢±ÙÀ» Á¦ÇÑÇϸç, ¼¼³î¸®Æ½ ¾à¹° ½ÃÀåÀÇ ¼ºÀå ¼Óµµ¸¦ ¾ïÁ¦ÇÕ´Ï´Ù.

COVID-19ÀÇ ¿µÇâ

COVID-19ÀÇ ´ëÀ¯ÇàÀº ÀÓ»ó½ÃÇèÀ» Áß´ÜÇÏ°í ¿¬±¸È°µ¿À» Áö¿¬½ÃŰ°í ·ÎÅ©´Ù¿î°ú ¾ÈÀü¿¡ ´ëÇÑ ¿ì·Á·ÎºÎÅÍ È¯ÀÚÀÇ Âü¿©¸¦ Á¦ÇÑÇÔÀ¸·Î½á ¼¼³î¸®Æ½ ¾à¹° ½ÃÀå¿¡ Å« ¿µÇâÀ» ÁÖ¾ú½À´Ï´Ù. Á¦¾àȸ»ç´Â °ø±Þ¸ÁÀÇ °úÁ¦¿¡ Á÷¸éÇÏ¿© ÀǾàǰ °³¹ßÀÇ ÁøÇàÀ» Áö¿¬½ÃÄ×½À´Ï´Ù. ±×·¯³ª À¯Çà ±â°£ µ¿¾È ³ëÈ­¿Í °ü·ÃµÈ Ãë¾à¼º°ú ¸¸¼º Áúȯ¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁü¿¡ µû¶ó ¼¼³î¸®Æ½ ¾à¹°ÀÇ °¡´É¼ºÀÌ °­Á¶µÇ¾î ´Ü±âÀûÀÎ ÈÄÅð¿¡µµ ºÒ±¸ÇÏ°í »õ·Î¿î °ü½É°ú Àå±â ÅõÀÚ ±âȸ°¡ ÃËÁøµÇ¾ú½À´Ï´Ù.

¿¹Ãø ±â°£ µ¿¾È Äɸ£¼¼Æ¾ ºÐ¾ß°¡ ÃÖ´ë°¡ µÉ Àü¸Á

Äɸ£¼¼Æ¾ ºÐ¾ß´Â È®¸³µÈ ¾ÈÀü¼º ÇÁ·ÎÆÄÀÏ, ÇÕ¸®ÀûÀÎ °¡°Ý, ±¤¹üÀ§ÇÑ Ä¡·á °¡´É¼ºÀ¸·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È ÃÖ´ë ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Ç×»êÈ­ ÀÛ¿ë°ú Ç׿°Áõ ÀÛ¿ëÀ¸·Î ¾Ë·ÁÁø Äɸ£¼¼Æ¾Àº ³ëÈ­ ¼¼Æ÷¸¦ È¿°úÀûÀ¸·Î Ç¥ÀûÈ­ÇÏ°í ³ëÈ­ °ü·Ã Áúȯ¿¡¼­ ³Î¸® ¿¬±¸µÇ°í ÀÖ½À´Ï´Ù. ¿µ¾çº¸Á¶½ÄǰÀ¸·Î ÀÔ¼ö°¡´ÉÇÏ°í ¼ÒºñÀÚÀÇ ÀÎÁöµµ°¡ ³ô¾ÆÁö°í ÀÖ´Â °Íµµ ½ÃÀåÀ» ¼±µµÇÏ´Â ¿äÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÀÓ»ó °ËÁõÀÌ ÁøÇàµÊ¿¡ µû¶ó, Äɸ£¼¼Æ¾Àº ÀǾàǰ°ú °Ç°­ ½Äǰ ¸ðµÎ¿¡ ÅëÇյǾî Áö¹èÀû ÁöÀ§°¡ °­È­µÉ °ÍÀÔ´Ï´Ù.

¿¹Ãø±â°£ µ¿¾È °ñ°üÀý¿° ºÐ¾ß°¡ °¡Àå ³ôÀº CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¿¹Ãø ±â°£ µ¿¾È °ñ°üÀý¿° ºÐ¾ß°¡ °¡Àå ³ôÀº ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµÇÁö¸¸, ÀÌ´Â Áúº´ º¯Çü Ä¡·á¿¡ ´ëÇÑ ±ä±ÞÇÑ ¿ä±¸ ¶§¹®ÀÔ´Ï´Ù. ¼¼³î¸®Æ½ ¾à¹°Àº °üÀýÁ¶Á÷ÀÇ ³ëÈ­¼¼Æ÷¸¦ Ç¥ÀûÀ¸·Î ÇÔÀ¸·Î½á ȹ±âÀûÀÎ Ä¡·á¹ýÀ» Á¦°øÇÏ¿© °üÀýÀÇ º¯¼ºÀ» ¿ªÀü½ÃÄÑ ¿îµ¿´É·ÂÀ» Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù. °ñ°üÀý¿°Àº ¼¼°è ¼ö¹é¸¸ ¸íÀ» ¾Î°í ÀÖÀ¸¸ç ÇöÀçÀÇ Ä¡·á¹ýÀº ´ëÁõ ¿ä¹ý¿¡ ±¹ÇÑµÇ¾î ¼¼³î¸®Æ½ ¾à¹°°¡ ÆÐ·¯´ÙÀÓ À̵¿À» ÀÏÀ¸Åµ´Ï´Ù. ³ëÀÎ Àα¸ Áõ°¡, ÀÓ»ó½ÃÇè Áõ°¡, ¿¬±¸ ÀÚ±Ý Áö¿øÀÌ Ã¤¿ëÀ» °¡¼ÓÈ­Çϰí ÀÖÀ¸¸ç,ÀÌ ºÐ¾ß´Â ½ÃÀåÀÇ ÁÖ¿ä ¼ºÀå ¿£ÁøÀ̵Ǿú½À´Ï´Ù.

ÃÖ´ë Á¡À¯À²À» Â÷ÁöÇÏ´Â Áö¿ª

¿¹Ãø ±â°£ µ¿¾È ¾Æ½Ã¾ÆÅÂÆò¾çÀº ±¤´ëÇÑ ³ëÀÎ Àα¸, ÀÇ·á ÅõÀÚ Áõ°¡, ¿¹¹æ ÀÇÇп¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁü¿¡ µû¶ó ÃÖ´ë ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀϺ», Áß±¹, Çѱ¹°ú °°Àº ±¹°¡µéÀº Á¦·Î °úÇÐ ¿¬±¸ ¹× »ý¸í °øÇÐ Çõ½ÅÀ» À̲ø°í ÀÖ½À´Ï´Ù. °Ç°­ÇÑ °í·ÉÈ­¸¦ ÃËÁøÇÏ´Â Á¤ºÎÀÇ ÀÌ´Ï¼ÅÆ¼ºêÀ̳ª Çаè¿Í »ê¾÷°èÀÇ Çù·Â °ü°è°¡ ½ÃÀåÀÇ È®´ë¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. °Ô´Ù°¡ ÀÌ Áö¿ªÀº Äɸ£¼¼Æ¾°ú °°Àº õ¿¬ È­ÇÕ¹°¿¡ °ü¿ëÀ̱⠶§¹®¿¡ ¼ÒºñÀÚÀÇ Ã¤¿ëÀÌ ÃËÁøµÇ°í ¾Æ½Ã¾ÆÅÂÆò¾çÀº ¼¼³î¸®Æ½ ¾à¹°ÀÇ °³¹ß¿¡ À־ Áö¹èÀû ¼¼·ÂÀ¸·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù.

°¡Àå ³ôÀº CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµÇ´Â Áö¿ª :

¿¹Ãø ±â°£ µ¿¾È ºÏ¹Ì°¡ °¡Àå ³ôÀº CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ´Â °ß°íÇÑ R&D ÀÎÇÁ¶ó, °­·ÂÇÑ »ý¸í°øÇÐ ÀÚ±Ý, Àû±ØÀûÀÎ ±ÔÁ¦ ȯ°æ¿¡ ´Þ·Á ÀÖ½À´Ï´Ù. ¹Ì±¹Àº Àα¸µ¿ÅÂÀÇ °í·ÉÈ­¿Í ¸¸¼ºÁúȯ Áõ°¡¿¡ ÈûÀÔ¾î ¼¼³î¸®Æ½ ¾à¹°ÀÇ ÀÓ»ó½ÃÇè°ú ƯÇã½Åû¿¡¼­ ¼±µµÇϰí ÀÖ½À´Ï´Ù. Á¦¾à ´ë±â¾÷°ú Çмú±â°ü°úÀÇ Àü·«Àû Á¦ÈÞ°¡ Çõ½ÅÀ» °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Àå¼ö ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ÒºñÀÚÀÇ Àνİú ¼ö¿ä°¡ ±ÞÁõÇϰí ÀÖÀ¸¸ç, ºÏ¹Ì´Â ±Þ¼ÓÇÑ »ó¾÷È­¿Í ½ÃÀå ¼ºÀåÀÇ ÇÖ½ºÆÌÀÌ µÇ°í ÀÖ½À´Ï´Ù.

¹«·á ¸ÂÃãÇü ¼­ºñ½º

ÀÌ º¸°í¼­¸¦ ±¸µ¶ÇÏ´Â °í°´Àº ´ÙÀ½ ¹«·á ¸ÂÃã¼³Á¤ ¿É¼Ç Áß Çϳª¸¦ »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ¼­·Ð

Á¦3Àå ½ÃÀå µ¿Ç⠺м®

Á¦4Àå Porter's Five Forces ºÐ¼®

Á¦5Àå ¼¼°èÀÇ ¼¼³î¸®Æ½ ¾à¹° ½ÃÀå : ¾à¹° À¯Çüº°

Á¦6Àå ¼¼°èÀÇ ¼¼³î¸®Æ½ ¾à¹° ½ÃÀå : ÀÛ¿ë±âÀüº°

Á¦7Àå ¼¼°èÀÇ ³ëÈ­ ¼¼Æ÷ Á¦°Å¾à ½ÃÀå : Åõ¿© °æ·Îº°

Á¦8Àå ¼¼°èÀÇ ¼¼³î¸®Æ½ ¾à¹° ½ÃÀå : ¿ëµµº°

Á¦9Àå ¼¼°èÀÇ ¼¼³î¸®Æ½ ¾à¹° ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

Á¦10Àå ¼¼°èÀÇ ¼¼³î¸®Æ½ ¾à¹° ½ÃÀå : Áö¿ªº°

Á¦11Àå ÁÖ¿ä ¹ßÀü

Á¦12Àå ±â¾÷ ÇÁ·ÎÆÄÀϸµ

KTH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

According to Stratistics MRC, the Global Senolytic Drugs Market is accounted for $58.5 million in 2025 and is expected to reach $552.5 million by 2032 growing at a CAGR of 37.8% during the forecast period. Senolytic drugs are therapeutic agents designed to selectively eliminate senescent cells-cells that have stopped dividing but remain metabolically active and contribute to aging and chronic diseases. By clearing these dysfunctional cells, senolytics aim to reduce inflammation, restore tissue function, and delay age-related decline. These compounds show promise in treating conditions like osteoarthritis, fibrosis, cardiovascular issues, and neurodegenerative disorders. Derived from natural sources or synthesized in labs, senolytics target specific survival pathways within senescent cells. As research progresses, they are emerging as transformative tools in longevity science, regenerative medicine, and preventive healthcare strategies focused on cellular rejuvenation.

Market Dynamics:

Driver:

Rising Prevalence of Age-Related Diseases

The rising prevalence of age-related diseases is significantly accelerating demand for senolytic drugs, positioning them as a vital innovation in modern therapeutics. Conditions like Alzheimer's, cardiovascular disorders, and osteoarthritis are propelling research and adoption of senescence-targeting treatments. As global populations age, healthcare systems increasingly seek effective, disease-modifying solutions. Senolytics, by addressing cellular aging at its root, are gaining traction as transformative agents and expanding clinical exploration, thereby driving robust market growth across pharmaceutical and wellness domains.

Restraint:

Limited Clinical Evidence and Regulatory Uncertainty

The senolytic drugs market faces major setbacks due to limited clinical evidence and regulatory uncertainty. The lack of robust, large-scale trials raises doubts about safety and efficacy, reducing trust among clinicians and patients. At the same time, unclear and evolving regulatory frameworks create barriers for approvals, delaying commercialization. These factors restrict investor confidence, slow research progress, and hinder the broader adoption of senolytic therapies despite their therapeutic potential.

Opportunity:

Growing Focus on Longevity and Healthy Aging

The growing focus on longevity and healthy aging is fueling unprecedented demand for senolytic drugs. As consumers and healthcare systems prioritize extending healthspan over lifespan, investment in cellular rejuvenation technologies has surged. Senolytics, by eliminating harmful senescent cells, align perfectly with preventive medicine and wellness trends. Their role in enhancing vitality, reducing age-related decline, and improving life quality is attracting interest across pharma, biotech, and nutraceutical sectors. This cultural and scientific shift is driving innovation, awareness, and market expansion globally.

Threat:

High Development Costs

High development costs pose a major hindrance to the Senolytic Drugs Market, as the complex research, extensive clinical trials, and regulatory requirements demand substantial financial investment. Smaller biotech firms often struggle to secure adequate funding, delaying innovation and product launches. These high expenses also increase risks for investors, slowing market expansion and limiting accessibility of potential therapies, thereby restricting the pace of advancements in the senolytic drugs landscape.

Covid-19 Impact

The Covid-19 pandemic significantly impacted the Senolytic Drugs Market by disrupting clinical trials, delaying research activities, and limiting patient participation due to lockdowns and safety concerns. Pharmaceutical companies faced supply chain challenges, slowing drug development progress. However, the heightened focus on age-related vulnerabilities and chronic illnesses during the pandemic emphasized the potential of senolytic therapies, driving renewed interest and long-term investment opportunities despite short-term setbacks.

The quercetin segment is expected to be the largest during the forecast period

The quercetin segment is expected to account for the largest market share during the forecast period, due to its established safety profile, affordability, and broad therapeutic potential. Known for its antioxidant and anti-inflammatory properties, quercetin effectively targets senescent cells and is widely studied in aging-related conditions. Its availability in dietary supplements and growing consumer awareness contribute to its market leadership. As clinical validation progresses, quercetin's integration into both pharmaceutical and wellness applications will reinforce its dominant position.

The osteoarthritis segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the osteoarthritis segment is predicted to witness the highest growth rate, due to urgent need for disease-modifying treatments. Senolytic drugs offer a breakthrough by targeting senescent cells in joint tissues, potentially reversing degeneration and improving mobility. With osteoarthritis affecting millions globally and current therapies limited to symptom management, senolytics present a paradigm shift. Rising geriatric populations, increased clinical trials, and supportive research funding are accelerating adoption, making this segment a key growth engine in the market.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share due to its vast aging population, rising healthcare investments, and growing interest in preventive medicine. Countries like Japan, China, and South Korea are leading in geroscience research and biotech innovation. Government initiatives promoting healthy aging and collaborations between academia and industry are fostering market expansion. Additionally, the region's openness to natural compounds like quercetin enhances consumer adoption, positioning Asia Pacific as a dominant force in senolytic development.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to robust R&D infrastructure, strong biotech funding, and a proactive regulatory environment. The U.S. leads in clinical trials and patent filings for senolytic therapies, supported by aging demographics and rising chronic disease prevalence. Strategic partnerships between pharmaceutical giants and academic institutions are accelerating innovation. Moreover, consumer awareness and demand for longevity solutions are surging, making North America a hotspot for rapid commercialization and market growth.

Key players in the market

Some of the key players profiled in the Senolytic Drugs Market include Unity Biotechnology, Oisin Biotechnologies, Senolytic Therapeutics, AgeX Therapeutics, Calico Life Sciences, BioAge Labs, Life Biosciences, Juvenescence, Human Longevity Inc., Insilico Medicine, Rejuvenate Bio, Alkahest, CohBar, Proteostasis Therapeutics, Recursion Pharmaceuticals, Restorbio, Sierra Sciences, Senex Biotechnology, Acorda Therapeutics and Cleara Biotech.

Key Developments:

In July 2025, Life Biosciences and Singapore's SingHealth Duke NUS Regenerative Medicine Institute (REMEDIS) have signed an MOU to jointly develop cellular rejuvenation therapies targeting age related diseases. By combining REMEDIS's translational expertise with Life Bio's Partial Epigenetic Reprogramming Platform, the collaboration aims to accelerate novel therapeutics across multiple organs, including eye and cardiovascular systems.

In June 2025, Juvenescence Limited acquired Ro5 Inc. enhancing its AI and machine learning drug discovery capabilities through Ro5's biomedical knowledge graph (~85 million nodes and 400 million relationships) and AI chemistry platform, accelerating its aging disease therapeutics pipeline in cognition, cardio metabolism, immunity and cellular repair.

Drug Types Covered:

Mechanism of Actions Covered:

Routes of Administration Covered:

Applications Covered:

End Users Covered:

Regions Covered:

What our report offers:

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Table of Contents

1 Executive Summary

2 Preface

3 Market Trend Analysis

4 Porters Five Force Analysis

5 Global Senolytic Drugs Market, By Drug Type

6 Global Senolytic Drugs Market, By Mechanism of Action

7 Global Senolytic Drugs Market, By Route of Administration

8 Global Senolytic Drugs Market, By Application

9 Global Senolytic Drugs Market, By End User

10 Global Senolytic Drugs Market, By Geography

11 Key Developments

12 Company Profiling

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â